Literature DB >> 28496607

QT Prolongation Following Ectopic Beats: Initial Data Regarding The Upper Limit Of Normal With Possible Implications For Antiarrhythmic Therapy And Concealed (Unexpressed) Long QT.

Alyssa J Reiffel1, James A Reiffel1.   

Abstract

Background: Ectopic beats are frequently associated with morphologic repolarization alterations of ensuing sinus beats. Less is known about repolarization duration alterations of post-ectopic sinus beats. In one patient who developed long QT and torsades de pointes upon exposure to a class III antiarrhythmic drug, and was later genotyped as being a carrier for long QT syndrome (LQTS) type 1, review of a pre-drug Holter monitor study revealed marked QT prolongation of post-ectopic sinus beats. In wondering whether this might be a common clue to "concealed" unexpressed LQTS, we realized that we must first characterize the range of post-ectopic QT prolongation present in normals. Prolongation beyond the upper limit of this range might then raise suspicion of possible LQTS and alter the antiarrhythmic drug selection process for the suppression of atrial fibrillation or other arrhythmias.
Methods: Accordingly, we assessed the presence/degree of repolarization prolongation following premature ectopic impulses in 166 subjects with normal conduction intervals and normal repolarization on their resting 12-lead ECG, 75 of whom had no known associated cardiovascular disorder of any kind. That is, in our subjects, the maximal prolongation of the QT interval of the sinus beat following isolated ventricular and atrial premature complexes was characterized.
Results: QT prolongation is common in post ectopic sinus beats. However, in our subjects the uncorrected QT interval of post-ectopic sinus beats never exceeded 480 ms in duration [which was much shorter than that seen (510-590 ms) in our gene carrier].
CONCLUSIONS: The QT interval in normal subjects may prolong following premature complexes but not to a value in excess of 480 ms.

Entities:  

Year:  2009        PMID: 28496607      PMCID: PMC5395038          DOI: 10.4022/jafib.113

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  7 in total

Review 1.  Long QT Syndrome.

Authors:  Arthur J Moss
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

2.  A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology.

Authors:  Martino Vaglio; Jean-Philippe Couderc; Scott McNitt; Xiaojuan Xia; Arthur J Moss; Wojciech Zareba
Journal:  Heart Rhythm       Date:  2007-08-28       Impact factor: 6.343

3.  Dynamics of QT interval in a patient with long QT syndrome and a normal QT interval.

Authors:  M Nakagawa; T Iwao; S Ishida; N Takahashi; H Yonemochi; M Asada; S Shimada; T Saikawa; M Ito
Journal:  Jpn Circ J       Date:  1998-03

4.  Effects of the ventricular activation sequence on the JT interval.

Authors:  J Banker; J Dizon; J Reiffel
Journal:  Am J Cardiol       Date:  1997-03-15       Impact factor: 2.778

5.  Autonomic nervous system influences on QT interval in normal subjects.

Authors:  Anthony R Magnano; Steve Holleran; Rajasekhar Ramakrishnan; James A Reiffel; Daniel M Bloomfield
Journal:  J Am Coll Cardiol       Date:  2002-06-05       Impact factor: 24.094

6.  Effect of premature ventricular beats on manual and automatic repolarization measurements.

Authors:  Stefania Vecchietti; Philip Langley; Stefano Severi; Silvio Cavalcanti; Alan Murray
Journal:  J Electrocardiol       Date:  2004-07       Impact factor: 1.438

7.  Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.

Authors:  Annukka Lehtonen; Heidi Fodstad; Päivi Laitinen-Forsblom; Lauri Toivonen; Kimmo Kontula; Heikki Swan
Journal:  Heart Rhythm       Date:  2007-01-18       Impact factor: 6.343

  7 in total
  1 in total

1.  Man versus machine? Acquired long QT syndrome in a patient with anorexia nervosa.

Authors:  Tomio Tran; Michael Brunnquell; Philip S Mehler; Mori J Krantz
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-09-24       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.